Inato Raises $20 Million in New Funding to Make Clinical Trials More Inclusive
Summary
PARIS and NEW YORK, March 29, 2023 Inato, the leading technology platform enabling access to inclusive clinical trials, today announced the close of $20 million in Series A2 funding from existing and new investors. This also enables sponsors to partner with a broader range of verified community research sites, decreasing competition, accelerating site activation, and increasing patient access.Our repeat investment in Inato represents our strong conviction in the companys mission, team, and continued success as an emerging leader and pioneer when it comes to changing the status quo in clinical trial diversity and access, said Jean-Fran\xe7ois Cochy, partner at Cathay Innovation. To do this, the Inato platform connects global pharmaceutical companies with a broader range of community research sites, while ensuring reliable high performance through collaborative, evidence-based enrollment planning and ongoing support. Its global platform unifies technology investment across continents, investors, entrepreneurs and leading corporations to accelerate startup growth with access to new markets, invaluable industry knowledge and introductions to potential partners from the start. As a multistage fund with over $2B assets under management and offices across San Francisco, New York, Paris, Shanghai, Beijing and Singapore, Cathay Innovation partners with visionary entrepreneurs and startups positively impacting the world through technology.
